financetom
Business
financetom
/
Business
/
Kimberly-Clark beats profit estimates on cost cuts, essential products demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kimberly-Clark beats profit estimates on cost cuts, essential products demand
Mar 11, 2026 1:46 AM

Jan 27 (Reuters) - Kimberly-Clark ( KMB ) exceeded quarterly profit expectations on Tuesday, helped by cost controls and steady demand for its products including Huggies diapers and Kleenex tissues.

Shares of the company, which had lost about 23% of their value in 2025, were ‌up about 2% in trading before the bell. 

The Dallas-based company has cut jobs and sold ​low-margin and non-essential businesses such as its private-label diaper and personal protective ‍equipment segments in recent months.

That has shielded margins ⁠as Kimberly-Clark ( KMB ) expands ⁠its affordable ranges and offers lower-priced products that still carry premium features to attract cost-conscious ‌customers and fight competition.

Prices declined 1.1% ​while organic sales rose 2.1% in the fourth quarter, driven by a 2.7% growth in overall volumes as consumers ⁠stocked up on essential products such ‍as surface ​cleaning agents, disinfectants and paper napkins at warehouse-style club stores that sell larger, value packs.     

The company, which had previously warned that ‍steep U.S. import duties, especially on Chinese goods, would hit profitability, posted an adjusted gross margin of 37%, in line with the prior year.

Adjusted earnings per share of $1.86 were above analysts' estimates of $1.81, according to data compiled by LSEG.

Net sales for the quarter ended December ​30 totaled $4.08 ‍billion, slightly shy of expectations of $4.09 billion. 

Consumer goods bellwether Procter & Gamble ( PG ) also exceeded quarterly earnings expectations last week, despite revenue ​slightly being short of expectations.

Kimberly-Clark ( KMB ) expects 2026 organic sales to be in line with or ahead of the roughly 2% average growth seen across the categories and markets it competes in. 

It expects adjusted profit per share to grow at a double-digit rate, with margins expanding as it improves efficiencies. 

The company has proposed ​buying Tylenol maker Kenvue ( KVUE ) for more than $40 billion to create a global consumer health company, with the deal expected to close by year-end.

(Reporting by Neil J Kanatt, Savyata Mishra ‍in Bengaluru and Jessica DiNapoli in New York; Editing by Devika Syamnath)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved